Investor Presentaiton

Department of Health Notes to the financial statements For the year ended on 30 June 2023 8.3 Fair value measurements (continued) Fair value measurements using significant unobservable inputs (Level 3) Contents Site Land $'000 Buildings $'000 infrastructure Total $'000 $'000 2023 Fair value at start of period 4,431 1,944 152 6,527 Additions Revaluation increments/(decrements) recognised in Other Comprehensive Income 379 325 704 Disposals Depreciation expense (81) (16) (97) Fair value at end of period 4,810 2,188 136 7,134 2022 Fair value at start of period 4,371 1,803 117 6,291 Additions Revaluation increments/(decrements) recognised in Other Comprehensive Income 60 215 51 326 Disposals Depreciation expense (74) (16) (90) Fair value at end of period 4,431 1,944 152 6,527 Valuation processes There were no changes in valuation techniques during the period. However, the valuation processes have been significantly impacted by the COVID-19 pandemic. Transfers in and out of a fair value level are recognised on the date of the event or change in circumstances that caused the transfer. Transfers are generally limited to assets newly classified as non-current assets held for sale as Treasurer's instructions require valuations of land, buildings and site infrastructure to be categorised within Level 3 where the valuations will utilise significant Level 3 inputs on a recurring basis. Land (Level 3 fair values) Fair value for restricted use land is based on comparison with market evidence for land with low level utility (high restricted use land). The relevant comparators of land with low level utility is selected by Landgate and represents the application of a significant Level 3 input in this valuation methodology. The fair value measurement is sensitive to values of comparator land, with higher values of comparator land correlating with higher estimated fair values of land. < 186 About us Significant issues Report on operations Agency performance Operational disclosures ⚫Key performance indicators Financial disclosures and compliance • Appendix

View entire presentation